Award details

Using a Designer Receptor Exclusively Activated by Designer Drug to define the role of short chain fatty acids in metabolic disease and inflammation

Reference	BB/L02781X/2
Principal Investigator / Supervisor	Professor Andrew Tobin
Co-Investigators / Co-Supervisors
Institution	University of Glasgow
Department	College of Medical, Veterinary, Life Sci
Funding type	Research
Value (£)	319,341
Status	Completed
Type	Research Grant
Start date	01/09/2017
End date	31/01/2020
Duration	29 months

Abstract

unavailable

Summary

unavailable

Impact Summary

Who will benefit from this research? This programme addresses the relationship between diet, the microbiota and well-being; an area that is currently of general interest to the public where there is an understanding that controlling the microbiota with probiotics has an impact on health. Miller, Milligan, and Tobin are experienced in public engagement (press releases/popular media), hence dissemination of the results to the general public will facilitate the broad impact of our studies. Associated with this is the possibility that the data generated here might have impact on government health policy particularly in the area of diet and well-being. The most immediate beneficiaries from the research, however, will be our industrial partner AstraZeneca. Although the work detailed in the proposal will be made publically available, AstraZeneca will have immediate access to the results, in advance of public presentation. This is likely to provide AstraZeneca benefits commensurate with their contribution to the project both via direct funding and 'in-kind' contributions. Once the work has been made publically available then the next set of beneficiaries will be the wider pharmaceutical industry. There is considerable interest in whether acute or more sustained pharmacological manipulation of FFAR2 and/or FFAR3 might result in effective control of both gut inflammatory and metabolic diseases and the studies that will be performed are likely to shed considerable light on these topics. The third group of beneficiaries from this research are the neutraceutical and food industries. This reflects their interest in the potential effectiveness of both pre- and pro-biotic strategies to maintain or improve health and the developing concept of 'functional foods'. How will they benefit from this research? The general public and government agencies will certainly benefit from a clearer understanding of the impact of diet on well-being. This might affect public dietary habits and government policy on good nutrition. The results will certainly benefit the pharmaceutical industry as a whole, many of who are targeting free fatty acid receptors in the control of obesity, type II diabetes and inflammation. Thus, validation of FFAR2 and FFAR3 as targets in these indications will benefit these companies. The simple fact AstraZeneca have provided support to allow for an Industrial Partnership Award highlights the strategic decision of the company to invest in fully defining the therapeutic potential of FFAR2 and FFAR3. Rapid access to the research findings will allow more informed decisions at a corporate level about investment in efforts to identify lead and candidate molecules to target FFAR2/3. Other pharmaceutical companies will benefit in a similar way, although without such immediate access to the results. Any drug discovery programme targeting chronic diseases such as diabetes and inflammation of the lower gut is inherently a long term endeavour (8-12 years) but the work proposed certainly has the potential to impact on quality of life and healthy aging. It is generally easier to obtain regulatory clearance in some aspects of 'food and nutrition', so it is possible, therefore, that the research here would impact decisions in the food and nutrition industries in a 3-5 year time scale. The project also has great potential in terms of staff training in that the PDRAs will benefit from opportunities to perform cutting edge research in a broad swathe of areas relevant to modern pharmacological studies, to enhance team working via the need to integrate work from two sites and three laboratories, and to interact directly with staff within a major international pharmaceutical company. This training is likely to be optimal to ensure the greatest range of subsequent career opportunities.

Committee	Research Committee D (Molecules, cells and industrial biotechnology)
Research Topics	Pharmaceuticals
Research Priority	X – Research Priority information not available
Research Initiative	X - not in an Initiative
Funding Scheme	X – not Funded via a specific Funding Scheme

Associated awards:

BB/L02781X/1 Using a Designer Receptor Exclusively Activated by Designer Drug to define the role of short chain fatty acids in metabolic disease and inflammation

BB/L027887/1 Using a 'Designer Receptor Exclusively Activated by Designer Drug' to define the role of short chain fatty acids in metabolic disease and inflammation

I accept the terms and conditions of use (opens in new window)

export PDF file

back to list new search